Dr Lal PathLabs

September 24, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 539524

Sub: Outcome of Board Meeting held on September 24, 2026
Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. September 24, 2026, inter-alia considered and approved the acquisition of 70% stake in **SN Genelab Private Limited** ("SN Gene") from its existing Shareholders. Post acquisition, SN Gene shall become a Subsidiary of the Company.

The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time is enclosed herewith as **"Annexure – A".**

The Board Meeting commenced at 04:40 P.M. (IST) and concluded at 05:11 P.M. (IST).

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Digitally signed by Vinay Gujral
Date: 2026.09.24 17:16:16 +05'30'

Vinay Gujral
Company Secretary & Compliance Officer
Encl.: As above

Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085, +91-11-30258600, **Fax:** +91-11-2788-2134
Corporate Office: Dr. Lal PathLabs Ltd., 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122 001, Haryana +91-124-3016-500, **Fax:** +91-124-4234-468
E-mail: lalpathlabs@lalpathlabs.com, **Web:** www.lalpathlabs.com, **CIN No.:** L74899DL1995PLC065388

SP

Annexure-A

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

SN	Particulars	Acquisition of Company
1	Name of the target entity, details in brief such as size, turnover etc.	SN Genelab Private Limited ("SN Gene") **Turnover:** FY 2026: 57.96 Crores FY 2025: 53.36 Crores FY 2024: 43.27 Crores
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No, the proposed acquisition does not fall within the ambit of related party transaction(s).
3	Industry to which the entity being acquired belongs	Diagnostics - Genomics
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To strengthen the Company's expertise in genomics and broaden its portfolio of advanced diagnostic services.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	The transaction will be completed by November 30, 2026.
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	Upto INR 168 Crores plus certain performance linked earn out capped at INR 31.5 Crores for 70% stake
9	Percentage of shareholding / control acquired and / or number of shares acquired	Acquisition of 70% stake from existing shareholders of SN Gene
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	SN Gene was incorporated on December 16, 2013, in the State of Gujarat and is engaged in business of providing Diagnostics - Genomics services. Turnover: As mentioned in Clause 1 above